細(xì)胞系來(lái)源的異種移植腫瘤模型（cell line-derived
xenograft，CDX）是將體外培養(yǎng)的人源腫瘤細(xì)胞接種至免疫缺陷小鼠體內(nèi)而構(gòu)建的模型，其具有建模時(shí)間短、重復(fù)性好、成本低等特點(diǎn)。作為經(jīng)典的體內(nèi)實(shí)驗(yàn)方法，CDX
腫瘤模型在腫瘤學(xué)研究和抗腫瘤藥物研發(fā)過(guò)程中有著極大的需求。
南模生物目前已建立龐大的 CDX 模型資源庫(kù)，包含200余種細(xì)胞系，覆蓋全身各類(lèi)組織器官，可提供多種有效的人源腫瘤細(xì)胞系異體移植藥效模型。
我們也可以為您提供腫瘤生長(zhǎng)曲線、體重曲線、生化指標(biāo)、病理檢測(cè)和 mRNA 、蛋白水平檢測(cè)等多種藥理評(píng)估手段，滿足您藥物藥效學(xué)評(píng)價(jià)分析的多種需求。
CDX腫瘤模型案例
Fig. In situ transplantation tumour model based on HepG2-Luc hepatocellular carcinoma cells (host mouse: M-NSG). a. Model tumourigenic curve versus body weight curve; b. Photograph of mouse liver; c. Mouse live imaging image.
Fig. Lung in situ graft tumour model constructed based on the human SHP-77-Luc lung cancer cell line.
Fig. Pancreatic in situ graft tumour model constructed based on the human PANC-1-Luc pancreatic cancer cell line.
Fig. Cervical transplantation in situ tumour model constructed based on the human Hela-Luc cervical cancer cell line.
Fig. In situ graft tumour model of glioma constructed based on the human U87MG glioma cell line.
Fig. In situ transplant tumour model of bladder cancer constructed based on the human RT112-Luc bladder cancer cell line.
Fig. Femoral injection bone metastasis model constructed based on the human MDA-MB-231-Luc breast cancer cell line.
CDX腫瘤藥效案例
Fig. Anti-tumour drug efficacy validation experiments using the CDX model of ovarian cancer cell line (SK-OV-3).
Fig. CAR-T cell therapy efficacy validation experiment using lung cancer cell line (A549) CDX model.
Fig. mRNA anti-tumor drug efficacy validation experiments using the CDX model of the B-lymphoblastic leukaemia cell line (Nalm6-Luc).
病人組織來(lái)源的異種移植腫瘤模型（patient-derivedxenografts，PDX）是將腫瘤患者的腫瘤組織移植至重癥免疫缺陷型小鼠體內(nèi)而形成的模型。PDX
模型可以較完整地保持患者腫瘤原有的生物學(xué)特征、病理分型、分子標(biāo)志物表達(dá)、基因突變類(lèi)型等，在臨床前實(shí)驗(yàn)中應(yīng)用廣泛。
南模生物具有多年的PDX構(gòu)建經(jīng)驗(yàn)，借助重度免疫缺陷小鼠M-NSG的高成瘤率，已成功構(gòu)建大量PDX模型，覆蓋全身各類(lèi)組織器官，可為您提供專(zhuān)業(yè)高效的PDX模型構(gòu)建服務(wù)。
